Updated French guidelines for diagnosis and management of pelvic inflammatory disease

Background: Pelvic inflammatory disease (PID) is commonly encountered in ă clinical practice. Objectives: To provide up-to-date guidelines on ă management of PID. Search strategy: An initial search of the Cochrane ă database, PubMed, and Embase was performed using keywords related to PID ă to identify reports in any language published between January 1990 and ă January 2012, with an update in May 2015. Selection criteria: All ă identified reports relevant to the areas of focus were included. Data ă collection and analysis: A level of evidence based on the quality of the ă data available was applied for each area of focus and used for the ă guidelines. Main results: PID must be suspected when spontaneous pelvic ă pain is associated with induced adnexal or uterine pain (grade C). ă Pelvic ultrasonography is necessary to exclude tubo-ovarian abscess ă (grade B). Microbiological diagnosis requires vaginal and endocervical ă sampling for molecular and bacteriological analysis (grade B). ă First-line treatment for uncomplicated PID combines ofloxacin and ă metronidazole for 14 days (grade B). Treatment of tubo-ovarian abscess ă is based on drainage if the collection measures more than 3 cm (grade ă B), with combined ceftriaxone, metronidazole, and doxycycline for 14-21 ă days. Conclusions: Current management of PID requires easily ă reproducible investigations and treatment, and thus can be applied ă worldwide. (C) 2016 International Federation of Gynecology and ă Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved.